目的 探討?zhàn)B血清腦顆粒聯合鹽酸氟桂利嗪膠囊治療急性腦梗死伴頭痛患者的療效。方法 110例急性腦梗死伴頭痛患者入院后隨機分為兩組，對照組（55例）給予鹽酸氟桂利嗪膠囊治療，5 mg/次，晚間服用；觀察組（55例）給予養(yǎng)血清腦顆粒聯合鹽酸氟桂利嗪膠囊治療，養(yǎng)血清腦顆粒4 g/次，3 次/d；鹽酸氟桂利嗪膠囊5 mg/次，晚間服用。療程均為4周。依據兩組療效，治療前和治療后2、4周的頭痛積分、日常生活能力（ADL）評分及治療期間不良反應情況，評價養(yǎng)血清腦顆粒聯合鹽酸氟桂利嗪膠囊治療急性腦梗死伴頭痛患者的療效。結果 觀察組治愈25例，顯效19例，有效6例，有效率90.9%，對照組患者治愈18例，顯效12例，有效13例，有效率78.2%，兩者相比，差異有統(tǒng)計學意義（P<0.05）。治療前，兩組頭痛程度積分和發(fā)作頻率積分相比，無統(tǒng)計學差異；治療后2、4周，兩組患者頭痛程度積分和發(fā)作頻率積分均明顯降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且觀察組頭痛程度積分和發(fā)作頻率均低于對照組，差異有統(tǒng)計學意義（P<0.05）。治療前，兩組ADL評分相比，無統(tǒng)計學差異；治療后2、4周，兩組ADL評分均明顯提高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且觀察組ADL評分高于對照組，差異有統(tǒng)計學意義（P<0.05）。治療期間，兩組不良反應發(fā)生率無統(tǒng)計學差異。結論 養(yǎng)血清腦顆粒聯合鹽酸氟桂利嗪膠囊對急性腦梗死伴頭痛患者具有較好的治療效果，能明顯減輕患者頭痛，減少頭痛發(fā)作頻率，提高患者日常生活能力，用藥具有安全性。

Objective Discuss the efficacy of Yangxueqingnao granule combined with Flunarizine Hydrochloride capsules in treatment of acute cerebral infarction with headache. Methods 110 patients with acute cerebral infarction with headache were selected, they were divided into two groups randomly. The control group (55 cases) was given Flunarizine Hydrochloride Capsules. The observation group (55 cases) was given Yangxueqingnao granule combined with Flunarizine Hydrochloride capsules. The efficacy of Yangxueqingnao granule combined with Flunarizine Hydrochloride capsules in treatment of acute cerebral infarction with headache was evaluated by the efficacy, headache symptom score, ADL scores and adverse reactions during treatment. Results 25 cases were cured in the observation group, markedly effective in 19 cases, effective in 6 cases, the effective rate was 90.9%; 18 cases were cured in the control group, markedly effective in 12 cases, effective in 13 cases, the effective rate was 78.2%. The effective rate was higher in the observation group (P<0.05). Before treatment, there were no statistical significance on headache scores in two groups. 2 and 4 weeks after treatment, the headache scores were decreased and the scores were lower in the observation group (P<0.05). Before treatment, there were no statistical significance on ADL scores between two groups. 2 and 4 weeks after treatment, the ADL scores were increased and the scores were higher in the observation group (P<0.05). During treatment, there were no statistical significance on adverse reaction between two groups. Conclusion Yangxueqingnao granule combined with Flunarizine Hydrochloride capsules have a good therapeutic effect on acute cerebral infarction with headache symptoms. The patients can significantly reduce headache and headache attack frequency. The therapy can improve the ability of daily life of patients with good safety.